AL
ACAD icon

Airain Ltd’s Acadia Pharmaceuticals ACAD Stock Holding History

Airain Ltd’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,712
Closed -$424K – 773
2016
Q4 		$424K Buy
+14,712
New +$389K 0.03% 407
2016
Q1 		– Sell
-21,026
Closed -$750K – 768
2015
Q4 		$750K Buy
+21,026
New +$741K 0.05% 361

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Airain Ltd's ACAD Position: Q1 2017 in Review

Airain Ltd sold out of Acadia Pharmaceuticals (ACAD) in Q1 2017, closing a stake of 14,712 shares — an estimated $424K sold.

Airain Ltd first reported a position in ACAD in Q4 2015 and held it in 2 quarters. The position peaked at $750K in Q4 2015. 219 funds tracked by Wall St. Rank hold ACAD as of Q1 2017.

  • Airain Ltd reported no remaining Acadia Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Airain Ltd sold 14,712 Acadia Pharmaceuticals shares in Q1 2017, an estimated $424K.
  • Airain Ltd first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Airain Ltd's Acadia Pharmaceuticals position peaked at $750K in Q4 2015.
  • 219 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2017.

Based on Airain Ltd's 13F filing for Q1 2017, filed 9 May 2017.